All Neoplasms, Patients With Cancer Who Start Immunotherapy
Conditions
Keywords
Immunotherapy, Cognition, Cancer
Brief summary
The investigator's longitudinal pilot study aims to evaluate for the first time the impact of immunotherapy on cognition in oncology. Due to the recent nature of immunotherapy, its side effects and impact on quality of life are still poorly understood and, to date, there is no published study evaluating the impact of immunotherapy on cognition in patients treated for cancer. The study consists of the passation of 3 neuropsychological assessments over a period of 6 months in cancer patients who start immunotherapy
Interventions
OTHERCognitive test passations
Tests : MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences
Sponsors
Centre Francois Baclesse
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over the age of 18, * Patient with cancer and having to initiate treatment with immunotherapy alone * Treatment with immunotherapy will include either an anti-PD1 / L1 or Anti CTLA4 monotherapy or combination, * Patients may have received other antitumor treatments other than immunotherapy but these should be stopped at the time of initiation of immunotherapy * Performance Status \<2 * Patient at the level of studies 3 end of primary studies minimum (Barbizet scale), * Mastery of the French language. * Patient affiliated to a social security system * Patient having attested in writing of his non-opposition to participate in the study
Exclusion criteria
* Previous treatment with immunotherapy * Another anti-tumor treatment underway * Primary cancer of the central nervous system or cerebral metastasis, symptomatics and not controlled * Abuse of alcohol or drug use * Severe visual and / or auditory deficiency, * Refusal of participation of the patient. * Patient deprived of liberty or under guardianship * Patient unable to follow the study for geographical, social or psychopathological reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in cognitive function (at least in a cognitive domain) | between inclusion and 3 months. | The proportion of patients who will have a reduction of scores in neuropsychological questionnaires (scores of MoCA2, Hopkins verbal learning test, WAIS-IV, Trail Making test, Stroop Symboles) |
Countries
France
Outcome results
None listed